Contact: [email protected]
* Studie on hold
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| ORIGAMI-1* | CRC (wt) | 2L | Anti-EGFR+MET; chemo + amivantamab |
| DO2.22.01 | NSCLC MET exon 14 skipping | From 1L | MET exon 14 skipping, no other mutations; DO-2 oral |
| BI1456-0001* | PDAC, melanoma | Several | BI 1831169 oncolytical virus VSV-GP intratumoral |
| PYX-201-101 | Several | Several | PYX-201: ADC (anti-EDB+fibronectin+auristatin); TNBC/HR+/HER2- BC/HNSCC (no prior cetuximab) |
| SC201 (VICTORIA-01)* | All solid, without liver m+ | >SOC | SOT201: Fusion protein, PD-1 targeted IL-15 agonist |
| U31402-277 (HERTHENA-PanTumor01) | Several | Several | U3-1402: Patritumab Deruxtecan (HER3-DXd), IV, Q3W Esophageal/Breast/Lung |
| BI1438-0007 (DAREON-7)* | NEC | 1L | BI764532 + etoposide + platinum in DLL3+ |
| CDR404-001 | HLA+MAGE-A4 | >SOC | CDR404: MHC specific T-cell engager; High-grade serous gynecological cancers/Synovial sarcoma/Soft-tissue sarcoma/squamous cell carcinoma/Ovarian/Uterine/other tumors with known HLA/MAGE-A4 status |
| JK06.1.01 | Several | Several | JK06: ADC (anti-5T4 + MMAE); Monotherapy: EGFRmut NSCLC/Sq. NSCLC/Endometrial Ca/Esophageal Ca/Non-sq. NSCLC/ Gastric Ca/HNSCC/Bladder Ca Combination with pembrolizumab +/- platinum chemotherapy: Sq. NSCLC, Non-sq. NSCLC (any PD-L1 status) |
| BI1479-0012 (Beamion BCGC-1) | mBC, mGEAC, mCRC HER2 amplification | Several | BI1810631: HER2 inhibitor; Monotherapy or in combination with T-DXd, T-DM1, trastuzumab, mFOLFOX, mFOLFOX + trastuzumab, zanidatamab, or trastuzumab + capecitabine |
| BI1479-0009 (Beamion PANTUMOR-1) | Several | >SOC | Monotherapy BI1810631: HER2 inhibitor; HER2 amplification (i.e., 6 copies by NGS): Urothelial/Biliary tract/Uterine/Cervical/Non-squamous NSCLC/Salivary gland/CRC/Agnostic or HER2 mutated: Urothelial/Biliary tract |
| INCB161734-101 | KRASG12D CRC, PDAC, NSCLC, Agnostic | 1L | INCB161734 (inhibitor of KRASG12D) in combination with cetuximab, cetuximab + folfox, cetuximab + folfiri, or INCA33890 |
| ALKOVE-1 | Solid tumors, ALK+ (except mNSCLC) | 2L or >SOC | Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 (phase 2) |
| PM54-A-001-22* | Several | Several | PM54 monotherapy (natural antitumor agent of marine origin); Cutaneous melanoma/HGSOC/Small cell carcinomas/NEC/MPM/HR+/HER2- BC |
| Bayer 22931 | MTAP-deletion NSCLC, PDAC | Several | BAY 3713372 (PRMT5 inhibitor) monotherapy |
| Geneo 2.0 | Advanced solid tumors or primary CNS tumors (Colorectal cohort closed) | N/A | The Added Value of Tissue or Liquid Biopsy NGS profiling in Advanced Solid Tumor Treatment Decisions (tumor tissue ≤ 2 years) |
| SNV1521-101 | Solid tumors harboring known deleterious or suspected deleterious mutations | < 4L | SNV1521 (selective inhibitor and trapper of the PARP1 enzyme) monotherapy: BRCA1/2, PALB2, and/or RAD51X mCRPC |
| 20240031* | KRAS altered NSCLC, CRC, and PDAC (except KRAS G12R and Q61R) | > SOC | AMG410 monotherapy (reversible small-molecule inhibitor that binds to WT and KRAS mutants) |
| INCA036873-101* | RCC, Lymphoma | > SOC | INCA036873 (human, Fc effector function–disabled human IgG1 bispecific antibody that can bind to CD70 and CD3) monotherapy or in combination (eg, VEGF, PD-1, or HIF-2α inhibitors) |
Research Team